About VDC: Leadership
Samuel Z. Goldhaber
Samuel Z. Goldhaber, MD, Professor of Medicine at Harvard Medical School, chairs the Venous Disease Coalition. Dr. Goldhaber is a Senior Staff Member of the Cardiovascular Medicine Division of Brigham and Women’s Hospital (BWH). He is Director of the BWH Venous Thromboembolism Research Group and serves as Principal Investigator of a broad range of randomized clinical trials and observational studies related to the prevention, treatment, and epidemiology of venous thromboembolism. Dr. Goldhaber is also Director of the BWH Anticoagulation Service, which cares for more than 2,000 patients.
The March 10, 2005, New England Journal of Medicine published his large clinical trial that described a new method using electronic alerts to enhance venous thromboembolism prophylaxis. This intervention reduced symptomatic DVT and PE by 41%, without an increase in bleeding complications. Dr. Goldhaber is also the Principal Investigator of an ongoing multicenter trial on Physician Alerts for patients at high risk of DVT or PE who are not receiving prophylaxis.
In May 2006, he co-chaired the 2-day Surgeon General’s Workshop on DVT, which was cosponsored by the National Heart Lung and Blood Institute (NHLBI). He also serves on the National Comprehensive Cancer Network and National Quality Forum to formulate new treatment and prevention guidelines for venous thromboembolism. He is President and one of four Founding Directors of the nonprofit North American Thrombosis Forum, one of the 19 organizations comprising the Venous Disease Coalition.
Dr Goldhaber co-directs three Harvard Medical School continuing medical education courses: 1) a 5-day course reviewing all aspects of cardiovascular medicine, 2) a 2-day course reviewing arterial and venous thrombosis and thromboembolism, and 3) a 1-day course that focuses on thrombosis prevention. He is an editorial board member of several journals, including Circulation.
